Printer Friendly

GLYCOFI/CENTOCOR EVALUATE GLYCOPROTEIN PRODUCTION.

GlycoFi, Lebanon, NH, has initiated a collaboration with Centocor, Inc, to determine the feasibility of producing a Centocor protein using GlycoFi's proprietary yeast-based glycoprotein production technology. Under the agreement, Centocor has the option to use the GlycoFi yeast-based production system for future protein expression in return for milestone payments and royalties to GlycoFi. Financial details were not disclosed. In an on-going research study funded by Centocor, GlycoFi and Centocor are also evaluating the use of GlycoFi technology for the production of an undisclosed Centocor antibody. These two collaborations combine GlycoFi's unique expression technology for the production of human glycoproteins, including antibodies, with Centocor's expertise in the area of therapeutic proteins.

About GlycoFi

GlycoFi, Inc. is a biotechnology company that leverages its pioneering protein production technology to develop, produce and commercialize next generation biotherapeutics, alone and in partnership with other leading biopharmaceutical companies.

About GlycoFi's Technology

Sugars, or glycosylation, on the surface of a protein are known to influence critical pharmaceutical properties of therapeutic proteins and monoclonal antibodies. GlycoFi is the leader in the area of glycosylation engineering in living systems, and its patented, scaleable technology uniquely allows its partners to create specific human glycosylation variants of any therapeutic glycoprotein. For the first time, GlycoFi and its partners can systematically research the impact of a protein's glycovariants on its pharmaceutical properties, enabling the optimization of biological activity, receptor binding, serum half-life, and potency of the drug candidate, thereby reducing the overall development risk of the project.

For more information, visit http://www.glycofi.com or call 603/643-8186, ext. 106.
COPYRIGHT 2005 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Geographic Code:1USA
Date:Jun 1, 2005
Words:259
Previous Article:NUVELO BEGINS PHASE 3 TRIAL OF ALFIMEPRASE FOR "LEG ATTACK".
Next Article:MAP PHARMACEUTICALS APPOINTS NELSON PRESIDENT/CEO.
Topics:


Related Articles
MORPHOSYS EXTENDS AGREEMENT WITH CENTOCOR.
BOLEX/CENTOCOR TO MANUFACTURE PROTEINS USING LEX SYSTEM.
Y's Therapeutics initiates Phase II clinical trial to evaluate YSPSL in prevention of delayed graft function.
Merck announces it has agreed to purchase two biotechnology firms that will help it discover and produce products.
Centocor, Schering-Plough revise agreement covering REMICADE, Golimumab.
GlycoFi obtains United States patent.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters